3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Everolimus
3
tislelizumab
1
surufatinib
1
romidepsin
1
regorafenib
1
pembrolizumab
1
pasireotide
1
lutetium Lu 177 dotatate
1
folfirinox
1
fludarabine phosphate
1
epothilone B
1
cixutumumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Specimen Handling
1
Radiosurgery
1
Octreotide
1
Magnetic Resonance Spectroscopy
1
Liver Transplantation
1
Lactones
1
LY2584702
1
Interleukin-13
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Erlotinib Hydrochloride
1
Embolization, Therapeutic
1
Doxorubicin
1
Depsipeptides
1
Cytokines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Clinical Trials, Phase II as Topic
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled